Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, shares some insights into the value of futility analysis and how this may benefit patients enrolled in clinical trials. While futility analysis can be helpful, Dr Hendrix highlights the importance of setting strict boundaries and being cautious when declaring futility, especially in the case of Alzheimer’s disease. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.